STOCKHOLM, Sept. 8, 2021 /PRNewswire/ -- Essity has today raised EUR 600m in the bond market under its Euro Medium Term Note (EMTN) program. The re-offer yield for the bond was 0.33% with a maturity date of September 15, 2029, corresponding to mid swaps +0.43 percentage points.
The bond offering was oversubscribed, and the transaction was placed with more than 70 investors.
The bonds will be listed on the on the official list of Luxembourg Stock Exchange. The purpose of the issue is to refinance maturing loans and to finance operations.
BNP Paribas, Citigroup, Crédit Agricole CIB and Deutsche Bank acted as joint bookrunners for the transaction.
CONTACT:
For further information, please contact:
Per Lorentz, Vice President Corporate Communications, +46 8 788 52 51, [email protected] Johan Karlsson, Vice President Investor Relations, +46 8 788 51 30, [email protected]
Children's Minnesota is proud to announce it has been re-designated as an "LGBTQ+ Healthcare Equality Leader" by the Human Rights Campaign Foundation (HRC). The designation was awarded in the 16th iteration of HRC's Healthcare Equality Index (HEI),...
Innoviva, Inc. ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic...
Prothena Corporation plc , a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2024 and provided...
Myomo, Inc. ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended...
QuidelOrtho Corporation (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first...
